1. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma;Wolchok;J Clin Oncol,2022
2. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma;Migden;N Engl J Med,2018
3. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma;Jansen;Ann Oncol,2019
4. Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB);Loo;J Clin Oncol,2021
5. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067;Hodi;J Clin Oncol,2022